β受体阻滞剂在中青年高血压中的应用

doi:10.12114/j.issn.1007-9572.2022.0527

摘要/Abstract

摘要： 流行病学数据显示，中青年高血压的患病率约为20%，并逐年上升。这可能与中青年人群工作压力大、精神紧张导致的交感神经兴奋有关，主要表现为以舒张压升高为主。中青年高血压与慢性冠心病或脑卒中明显相关，积极治疗可明显降低患者的长期心血管疾病发生率和死亡风险。β受体阻滞剂通过抑制交感神经活性降低血压，更适用于舒张压升高为主的中青年高血压患病人群。本文通过回顾文献分析了中青年高血压的流行病学数据、潜在机制及临床意义，探讨了β受体阻滞剂在中青年高血压患者管理中的主要作用及应用要点，为临床医生治疗中青年高血压提供参考。

关键词: 高血压, 抗高血压药, 肾上腺素能β受体拮抗剂, 中青年, β受体阻滞剂, 综述

Abstract:

Hypertension in young and middle-aged populations has a prevalence of approximately 20% according to relevant epidemiological reports, and is increasing in the light of the annual update, which is probably related to sympathetic excitation induced by stressful workloads and nervousness, and mainly characterized by elevated diastolic hypertension. There is an evident correlation between hypertension and long-term risk of coronary heart disease or stroke in the populations, but the long-term risk for cardiovascular events and mortality could be significantly reduced by active and appropriate antihypertensive treatment. β-blockers are medications that reduce blood pressure via inhibiting sympathetic activity, which are more suitable for young and middle-aged people primarily with diastolic hypertension. We did a review of the latest advances in epidemiology and pathogenesis of hypertension and major antihypertensive efficacies of β-blockers as well as precautions during the use of β-blockers in young and middle-aged populations, providing clinicians with evidence on treating the disease.

Key words: Hypertension, Antihypertensive agents, Adrenergic beta-antagonists, Young and middle-age, β-blockers, Review

李海瑞,彭伟,巫少荣. β受体阻滞剂在中青年高血压中的应用[J]. 中国全科医学, 2023, 26(02): 248-254. DOI: 10.12114/j.issn.1007-9572.2022.0527.
LI Hairui,PENG Wei,WU Shaorong. The Use of β-blockers in the Management of Hypertension in Young and Middle-aged People[J]. Chinese General Practice, 2023, 26(02): 248-254. DOI: 10.12114/j.issn.1007-9572.2022.0527.

参考文献 64

[1]	BATTISTONI A，CANICHELLA F，PIGNATELLI G，et al. Hypertension in young people：epidemiology，diagnostic assessment and therapeutic approach[J]. High Blood Press Cardiovasc Prev，2015，22（4）：381-388. DOI：10.1007/s40292-015-0114-3.
[2]	DE VENECIA T，LU M，FIGUEREDO V M. Hypertension in young adults[J]. Postgrad Med，2016，128（2）：201-207. DOI：10.1080/00325481.2016.1147927.
[3]	Writing Group Members，LLOYD-JONES D，ADAMS R J，et al. Heart disease and stroke statistics—2010 update：a report from the American Heart Association[J]. Circulation，2010，121（7）：e46-215. DOI：10.1161/CIRCULATIONAHA.109.192667.
[4]	MILLS K T，STEFANESCU A，HE J. The global epidemiology of hypertension[J]. Nat Rev Nephrol，2020，16（4）：223-237. DOI：10.1038/s41581-019-0244-2.
[5]	WHO. Hypertension-Key facts[EB/OL]. （2021-08-25）[2022-05-06].
[6]	GBD 2017 Mortality Collaborators. Global，regional，and national age-sex-specific mortality and life expectancy，1950-2017：a systematic analysis for the Global Burden of Disease Study 2017[J]. Lancet，2018，392（10159）：1684-1735. DOI：10.1016/S0140-6736(18)31891-9.
[7]	GBD 2016 Mortality Collaborators. Global，regional，and national under-5 mortality，adult mortality，age-specific mortality，and life expectancy，1970-2016：a systematic analysis for the Global Burden of Disease Study 2016[J]. Lancet，2017，390（10100）：1084-1150. DOI：10.1016/S0140-6736(17)31833-0.
[8]	WANG Z W，CHEN Z，ZHANG L F，et al. Status of hypertension in China：results from the China hypertension survey，2012-2015[J]. Circulation，2018，137（22）：2344-2356. DOI：10.1161/CIRCULATIONAHA.117.032380.
[9]	WANG J W，ZHANG L X，WANG F，et al. Prevalence，awareness，treatment，and control of hypertension in China：results from a national survey[J]. Am J Hypertens，2014，27（11）：1355-1361. DOI：10.1093/ajh/hpu053.
[10]	GAO Y，CHEN G，TIAN H，et al. Prevalence of hypertension in China：a cross-sectional study[J]. PLoS One，2013，8（6）：e65938. DOI：10.1371/journal.pone.0065938.
[11]	李镒冲，王丽敏，姜勇，等. 2010年中国成年人高血压患病情况[J]. 中华预防医学杂志，2012，46（5）：409-413. DOI：10.3760/cma.j.issn.0253-9624.2012.05.007.
[12]	HINTON T C，ADAMS Z H，BAKER R P，et al. Investigation and treatment of high blood pressure in young people：too much medicine or appropriate risk reduction?[J]. Hypertension，2020，75（1）：16-22. DOI：10.1161/HYPERTENSIONAHA.119.13820.
[13]	WILLIAMS B，MANCIA G，SPIERING W，et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension[J]. Eur Heart J，2018，39（33）：3021-3104. DOI：10.1093/eurheartj/ehy339.
[14]	LORIA C M，LIU K，LEWIS C E，et al. Early adult risk factor levels and subsequent coronary artery calcification：the CARDIA Study[J]. J Am Coll Cardiol，2007，49（20）：2013-2020. DOI：10.1016/j.jacc.2007.03.009.
[15]	LI D，ZENG X F，HUANG Y，et al. Increased risk of hypertension in young adults in southwest China：impact of the 2017 ACC/AHA high blood pressure guideline[J]. Curr Hypertens Rep，2019，21（3）：21. DOI：10.1007/s11906-019-0926-y.
[16]	GUO J，ZHU Y C，CHEN Y P，et al. The dynamics of hypertension prevalence，awareness，treatment，control and associated factors in Chinese adults：results from CHNS 1991-2011[J]. J Hypertens，2015，33（8）：1688-1696. DOI：10.1097/HJH.0000000000000594.
[17]	GRASSI G，MARK A，ESLER M. The sympathetic nervous system alterations in human hypertension[J]. Circ Res，2015，116（6）：976-990. DOI：10.1161/CIRCRESAHA.116.303604.
[18]	BAO W，THREEFOOT S A，SRINIVASAN S R，et al. Essential hypertension predicted by tracking of elevated blood pressure from childhood to adulthood：the Bogalusa Heart Study[J]. Am J Hypertens，1995，8（7）：657-665. DOI：10.1016/0895-7061(95)00116-7.
[19]	YAN L L，LIU K，MATTHEWS K A，et al. Psychosocial factors and risk of hypertension：the Coronary Artery Risk Development in Young Adults （CARDIA） study[J]. JAMA，2003，290（16）：2138-2148. DOI：10.1001/jama.290.16.2138.
[20]	董火林. 106例青年高血压病的临床分析[J]. 中原医刊，2005，32（22）：15-16. DOI：10.3760/cma.j.issn.1674-4756.2005.22.009.
[21]	GARAFOVA A，PENESOVA A，CIZMAROVA E，et al. Cardiovascular and sympathetic responses to a mental stress task in young patients with hypertension and/or obesity[J]. Physiol Res，2014，63（Suppl 4）：S459-467. DOI：10.33549/physiolres.932931.
[22]	PARFENOV V A，OSTROUMOVA T M，OSTROUMOVA O D，et al. Features of the clinical picture in patients of middle age with essential hypertension[J]. Ter Arkh，2018，90（9）：15-26. DOI：10.26442/terarkh201890915-26.
[23]	时新艳，郭红霞，赵晓东. 原发性高血压合并室性心律失常患者窦性心律震荡和血压变异性分析[J]. 中国现代医学杂志，2013，23（29）：85-88. DOI：10.3969/j.issn.1005-8982.2013.29.018.
[24]	FALKSTEDT D，KOUPIL I，HEMMINGSSON T. Blood pressure in late adolescence and early incidence of coronary heart disease and stroke in the Swedish 1969 conscription cohort[J]. J Hypertens，2008，26（7）：1313-1320. DOI：10.1097/HJH.0b013e3282ffb17e.
[25]	MIURA K，DAVIGLUS M L，DYER A R，et al. Relationship of blood pressure to 25-year mortality due to coronary heart disease，cardiovascular diseases，and all causes in young adult men：the Chicago Heart Association Detection Project in Industry[J]. Arch Intern Med，2001，161（12）：1501-1508. DOI：10.1001/archinte.161.12.1501.
[26]	GRAY L，LEE I M，SESSO H D，et al. Blood pressure in early adulthood，hypertension in middle age，and future cardiovascular disease mortality：HAHS （Harvard Alumni Health Study）[J]. J Am Coll Cardiol，2011，58（23）：2396-2403. DOI：10.1016/j.jacc.2011.07.045.
[27]	霍勇. 重视我国中青年高血压患者的管理[J]. 中华高血压杂志，2016，24（4）：320-323. DOI：10.16439/j.cnki.1673-7245.2016.04.009.
[28]	TALER S J. Epidemiological versus trial evidence for hypertension treatment：adding a piece to the puzzle[J]. J Am Coll Cardiol，2018，72（11）：1211-1213. DOI：10.1016/j.jacc.2018.07.011.
[29]	MARTELL-CLAROS N，GALGO-NAFRIA A，GROUP O S. Cardiovascular risk profile of young hypertensive patients：the OPENJOVEN study[J]. Eur J Prev Cardiol，2012，19（3）：534-540. DOI：10.1177/1741826711406202.
[30]	MCCARRON P，SMITH G D，OKASHA M，et al. Blood pressure in young adulthood and mortality from cardiovascular disease[J]. Lancet，2000，355（9213）：1430-1431. DOI：10.1016/S0140-6736(00)02146-2.
[31]	BULPITT C J，PALMER A J，FLETCHER A E，et al. Proportion of patients with isolated systolic hypertension who have burned-out diastolic hypertension[J]. J Hum Hypertens，1995，9（8）：675-678.
[32]	FRANKLIN S S，PIO J R，WONG N D，et al. Predictors of new-onset diastolic and systolic hypertension：the Framingham heart study[J]. Circulation，2005，111（9）：1121-1127. DOI：10.1161/01.CIR.0000157159.39889.EC.
[33]	PETROVITCH H，CURB J D，BLOOM-MARCUS E. Isolated systolic hypertension and risk of stroke in Japanese-American men[J]. Stroke，1995，26（1）：25-29. DOI：10.1161/01.str.26.1.25.
[34]	LI Y，WEI F F，WANG S，et al. Cardiovascular risks associated with diastolic blood pressure and isolated diastolic hypertension[J]. Curr Hypertens Rep，2014，16（11）：489. DOI：10.1007/s11906-014-0489-x.
[35]	HANSSON L，ZANCHETTI A，CARRUTHERS S G，et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension：principal results of the Hypertension Optimal Treatment（HOT）randomised trial. HOT Study Group[J]. Lancet，1998，351（9118）：1755-1762. DOI：10.1016/s0140-6736(98)04311-6.
[36]	MUSINI V M，GUEYFFIER F，PUIL L，et al. Pharmacotherapy for hypertension in adults aged 18 to 59 years[J]. Cochrane Database Syst Rev，2017，8：CD008276. DOI：10.1002/14651858.CD008276.pub2.
[37]	LAWES C M M，RODGERS A，BENNETT D A，et al. Blood pressure and cardiovascular disease in the Asia Pacific region[J]. J Hypertens，2003，21（4）：707-716. DOI：10.1097/00004872-200304000-00013.
[38]	施仲伟，冯颖青，王增武，等. β受体阻滞剂在高血压应用中的专家共识[J]. 中华高血压杂志，2019，27（6）：516-524. DOI：10.16439/j.cnki.1673-7245.2019.06.006.
[39]	GRASSI G. Metoprolol in the treatment of cardiovascular disease：a critical reappraisal[J]. Curr Med Res Opin，2018，34（9）：1635-1643. DOI：10.1080/03007995.2018.1479245.
[40]	DAHLÖF B，DEVEREUX R B，KJELDSEN S E，et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study（LIFE）：a randomised trial against atenolol[J]. Lancet，2002，359（9311）：995-1003. DOI：10.1016/S0140-6736(02)08089-3.
[41]	DAHLÖF B，SEVER P S，POULTER N R，et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required，in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm（ASCOT-BPLA）：a multicentre randomised controlled trial[J]. Lancet，2005，366（9489）：895-906. DOI：10.1016/S0140-6736(05)67185-1.
[42]	LINDHOLM L H，CARLBERG B，SAMUELSSON O. Beta blockers in primary hypertension：do age and type of beta-blocker matter?[J]. J Hypertens，2006，24（11）：2143-2145. DOI：10.1097/01.hjh.0000249686.65994.97.
[43]	郭艺芳. β受体阻滞剂是否可以继续作为一线降压药物[J]. 中华高血压杂志，2014，22（12）：1108-1113. DOI：10.16439/j.cnki.1673-7245.2014.12.037.
[44]	UNGER T，BORGHI C，CHARCHAR F，et al. 2020 international society of hypertension global hypertension practice guidelines[J]. Hypertension，2020，75（6）：1334-1357. DOI：10.1161/HYPERTENSIONAHA.120.15026.
[45]	施仲伟，冯颖青，林金秀，等. 高血压患者心率管理中国专家共识[J]. 中国医学前沿杂志（电子版），2017，9（8）：29-36. DOI：10.12037/YXQY.2017.08-06.
[46]	LEUNG A A，DASKALOPOULOU S S，DASGUPTA K，et al. Hypertension Canada's 2017 guidelines for diagnosis，risk assessment，prevention，and treatment of hypertension in adults[J]. Can J Cardiol，2017，33（5）：557-576. DOI：10.1016/j.cjca.2017.03.005.
[47]	《中国高血压防治指南》修订委员会. 中国高血压防治指南2018年修订版[J]. 心脑血管病防治，2019，19（1）：1-44. DOI：10.3969/j.issn.1009-816X.2019.01.001.
[48]	王鸿懿，孙宁玲. 2015中国台湾地区高血压管理指南介绍[J]. 中国医学前沿杂志（电子版），2015，7（1）：26-39.
[49]	KUYPER L M，KHAN N A. Atenolol vs nonatenolol β-blockers for the treatment of hypertension：a meta-analysis[J]. Can J Cardiol，2014，30（5）：S47-53. DOI：10.1016/j.cjca.2014.01.006.
[50]	LAW M R，WALD N J，MORRIS J K，et al. Value of low dose combination treatment with blood pressure lowering drugs：analysis of 354 randomised trials[J]. BMJ，2003，326（7404）：1427. DOI：10.1136/bmj.326.7404.1427.
[51]	The IPPPSH Collaborative Group. Cardiovascular risk and risk factors in a randomized trial of treatment based on the beta-blocker oxprenolol：the International Prospective Primary Prevention Study in Hypertension （IPPPSH）[J]. J Hypertens，1985，3（4）：379-392. DOI：10.1097/00004872-198508000-00011.
[52]	Medical research Council Working Party. MRC trial of treatment of mild hypertension：principal results[J]. BMJ，1985，291（6488）：97-104. DOI：10.1136/bmj.291.6488.97.
[53]	UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes：UKPDS 38[J]. BMJ，1998，317（7160）：703-713.
[54]	WILHELMSEN L，BERGLUND G，ELMFELDT D，et al. Beta-blockers versus diuretics in hypertensive men：main results from the HAPPHY trial[J]. J Hypertens，1987，5（5）：561-572. DOI：10.1097/00004872-198710000-00009.
[55]	WIKSTRAND J，WARNOLD I，OLSSON G，et al. Primary prevention with metoprolol in patients with hypertension. Mortality results from the MAPHY study[J]. JAMA，1988，259（13）：1976-1982.
[56]	WIKSTRAND J，WARNOLD I，TUOMILEHTO J，et al. Metoprolol versus thiazide diuretics in hypertension. Morbidity results from the MAPHY Study[J]. Hypertension，1991，17（4）：579-588. DOI：10.1161/01.hyp.17.4.579.
[57]	CELIK T，IYISOY A，ACIKEL C，et al. The comparative effects of metoprolol and perindopril on aortic elasticity in young patients with prehypertension[J]. Blood Press Monit，2008，13（3）：169-176. DOI：10.1097/MBP.0b013e3282fed786.
[58]	PAZ M A，DE-LA-SIERRA A，SÁEZ M，et al. Treatment efficacy of anti-hypertensive drugs in monotherapy or combination：ATOM systematic review and meta-analysis of randomized clinical trials according to PRISMA statement[J]. Medicine（Baltimore），2016，95（30）：e4071. DOI：10.1097/MD.0000000000004071.
[59]	TURNBULL F，Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events：results of prospectively-designed overviews of randomised trials[J]. Lancet，2003，362（9395）：1527-1535. DOI：10.1016/s0140-6736(03)14739-3.
[60]	SAINANI G，MEHTA N. Beta blockers are good choice as first line antihypertensive agents[J]. J Clin Prev Cardiol，2013，2（2）：101-105.
[61]	LAROCHELLE P，TOBE S W，LACOURCIÈRE Y. Β-Blockers in hypertension：studies and meta-analyses over the years[J]. Can J Cardiol，2014，30（5 Suppl）：S16-22. DOI：10.1016/j.cjca.2014.02.012.
[62]	LIU J，LU X，CHEN L，et al. Expert consensus on the management of hypertension in the young and middle-aged Chinese population[J]. Int J Clin Pract，2019：e13426. DOI：10.1111/ijcp.13426.
[63]	Highlights of prescribing information. TOPROL-XL（metoprolol succinate）tablet，extended release for oral use[EB/OL]. （2019-06-27）[2022-05-06].
[64]	SILVESTRI A，GALETTA P，CERQUETANI E，et al. Report of erectile dysfunction after therapy with beta-blockers is related to patient knowledge of side effects and is reversed by placebo[J]. Eur Heart J，2003，24（21）：1928-1932. DOI：10.1016/j.ehj.2003.08.016.